This commentary critically examines the long-standing emphasis on amyloid-β (Aβ)-based therapies in Alzheimer’s disease (AD), despite numerous clinical trial failures. It highlights the urgency to reassess research methodologies and challenges the initiation of anti-Aβ trials in preclinical stages of the disease without conclusive proofs of their safety and efficacy. Instead, a comprehensive approach that considers Aβ’s physiological roles and addresses AD complex nature is suggested, encouraging the idea that clinical trial failures may result from targeting the wrong mechanism. Evidence-based scientific research is needed to advance with AD treatment, moving beyond the current conception of Aβ hypothesis.
OhnoM (2024) A strategy for allowing earlier diagnosis and rigorous evaluation of BACE1 inhibitors in preclinical Alzheimer’s disease. J Alzheimers Dis99, 431–445.
2.
WesselsAM, LinesC, SternRA, KostJ, VossT, MozleyLH, FurtekC, MukaiY, AisenPS, CummingsJL, TariotPN, VellasB, DupreN, RandolphC, MichelsonD, AndersenSW, SheringC, SimsJR, EganMF (2020) Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease. Alzheimers Dement16, 1483–1492.
3.
MullardA (2018) BACE failures lower AD expectations, again. Nat Rev Drug Discov17, 385.
4.
BatemanRJ, SmithJ, DonohueMC, DelmarP, AbbasR, SallowayS, WojtowiczJ, BlennowK, BittnerT, BlackSE, KleinG, BoadaM, GrimmerT, TamaokaA, PerryRJ, TurnerRS, WatsonD, WoodwardM, ThanasopoulouA, LaneC, BaudlerM, FoxNC, CummingsJL, FontouraP, DoodyRS; GRADUATE I and II Investigators and the Gantenerumab Study Group
(2023) Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N Engl J Med389, 1862–1876.
5.
KnopmanDS, JonesDT, GreiciusMD (2021) Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement17, 696–701.
AtwoodCS, PerryG (2023) Playing Russian roulette with Alzheimer’s disease patients: Do the cognitive benefits of lecanemab outweigh the risk of edema, stroke and encephalitis?J Alzheimers Dis92, 799–801.
8.
HeidebrinkJL, PaulsonHL (2024) Lessons learned from approval of aducanumab for Alzheimer’s disease. Annu Rev Med75, 99–111.
9.
Plascencia-VillaG, PerryG (2023) Lessons from antiamyloid-β immunotherapies in Alzheimer’s disease. Handb Clin Neurol193, 267–292.
10.
Yeo-TehNSL, TangBL (2023) A review of scientific ethics issues associated with the recently approved drugs for Alzheimer’s disease. Sci Eng Ethics29, 2.
11.
VollochV, Rits-VollochS (2023) Effect of lecanemab in early Alzheimer’s disease: Mechanistic interpretation in the amyloid cascade hypothesis 2.0 perspective. J Alzheimers Dis93, 1277–1284.
12.
EspayAJ, HerrupK, ImbimboBP, KeppKP, DalyT (2024) Recalibrating the risk-benefit profiles of lecanemab and donanemab: Scales, immunoreactivity, and changes in amyloid-β42. J Alzheimers Dis99, 877–881.
13.
PuzzoD, ContiF (2021) Conceptual and methodological pitfalls in experimental studies: An overview, and the case of Alzheimer’s disease. Front Mol Neurosci14, 684977.
14.
GulisanoW, MaugeriD, BaltronsMA, FàM, AmatoA, PalmeriA, D’AdamioL, GrassiC, DevanandDP, HonigLS, PuzzoD, ArancioO (2018) Role of amyloid-β and tau proteins in Alzheimer’s disease: Confuting the amyloid cascade. J Alzheimers Dis64(s1), S611–S631.
15.
MakinS (2018) The amyloid hypothesis on trial. Nature. 559, S4–S7.
16.
PuzzoD, GulisanoW, ArancioO, PalmeriA (2015) The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience307, 26–36.
17.
PuzzoD, PriviteraL, Fa’M, StaniszewskiA, HashimotoG, AzizF, SakuraiM, RibeEM, TroyCM, MerckenM, JungSS, PalmeriA, ArancioO (2011) Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol69, 819–830.
18.
TropeaMR, Li PumaDD, MeloneM, GulisanoW, ArancioO, GrassiC, ContiF, PuzzoD (2021) Genetic deletion of α7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer’s disease-like pathology. Prog Neurobiol206, 102154.
